ASH Clinical News Advances in Hematology Research & Patient Care: Hi | Page 3
JANUARY 2016
AMERICAN SOCIETY OF HEMATOLOGY
HEADQUARTERS
2021 L Street NW, Suite 900
Washington, DC 20036
www.hematology.org
Tel: 202-776-0544
EDITOR-IN-CHIEF
Mikkael Sekeres, MD, MS
Vice-Chair for Clinical Research
Director, Leukemia Program
Cleveland Clinic, Taussig Cancer Institute
Cleveland, OH
ASSOCIATE EDITORS
Beth Faiman, CNP, PhD
Cleveland Clinic
Cleveland, OH
Alice Ma, MD
University of North Carolina School of Medicine
Chapel Hill, NC
CONTENTS
David Steensma, MD
Dana-Farber Cancer Institute
Boston, MA
Keith Stewart, MBChB, MBA
Mayo Clinic
Scottsdale, AZ
INTERVIEWS
6
7
Dr. Rodgers on the future directions and
challenges in treating sickle cell disease.
PUBLISHER
American Medical Communications
EDITORIAL
Griffin Rodgers, MD
Jill Johnsen, MD
Dr. Johnsen shares her insight into
translating genetic information into caring
for hematologic patients.
CLINICAL NEWS
MANAGING EDITORS
Ariel Jones-DeMaio, AMC
Karen Learner, ASH
12 GBT440: A New Option for Patients with
Sickle Cell Disease
16 New Options for Older Patients with Hodgkin
Lymphoma
ASSOCIATE MANAGING EDITOR
Kerri Fitzgerald, AMC
13
N-Acetylcysteine Increases Platelet Counts
in TTP
17 Over-Reporting of At-Home Chemotherapy
Adherence Using Self-Reporting Methods
13 Pracinostat Added to Azacitidine in MDS: No
Clinical Benefit, But Added Toxicity
18 Patient-Centered Outcomes One Year After
Pulmonary Embolism
DIGITAL PROJECTS MANAGER
Chris Gedikli
14 Eltrombopag in Patients with Lower-Risk MDS
and Thrombocytopenia
19
ADVERTISING
15
ART DIRECTOR
Ari Mihos
ASSISTANT ART DIRECTOR
Charlene DePrizio
ACCOUNT MANAGER
Nick Luciano
[email protected]
Gene Conselyea
[email protected]
Recruitment advertising orders can be sent to:
DIRECTOR, RECRUITMENT CLASSIFIEDS
Lauren Morgan
[email protected]
©2016 by the American Society of Hematology.
All materials contained in this newsletter are protected
by copyright laws and may not be used, reproduced, or
otherwise exploited in any manner without the express
prior written permission of ASH Clinical News. Any
third-party materials communicated to ASH Clinical
News become its copyrighted property and may be used,
reproduced, or otherwise exploited by ASH Clinical News.
PET-Guided Chemotherapy De-Escalation in
Hodgkin Lymphoma
Predicting Osteonecrosis in Children with ALL
20 Ibrutinib Safe, Effective in Older Patients with
CLL/SLL
21
Lumiere: Alisertib in Relapsed/Refractory PTCL
All correspondence for the American Society of Hematology should be sent to: American Society of Hematology,
2021 L Street NW, Suite 900, Washington DC 20036.
Neither the American Society of Hematology nor the publisher is responsible for statements made by any editor or contributor. Statements, editorials, or opinions expressed in ASH Clinical News magazine do not necessarily represent official
policy of the American Society of Hematology unless so stated. No responsibility is assumed by the American Society of
Hematology or the Publisher for any injury or damage to persons or property as a matter of product liability, negligence or
otherwise or from any use or operation of any methods, products, instructions or ideas contained in the material herein.
Although all advertising material published in ASH Clinical News magazine is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement by the American Society
of Hematology or the Publisher of the quality or value of such product or of the claim made of it by its manufacturer.
About the American Society of Hematology
The American Society of Hematology (ASH) is the world’s largest professional society concerned with the causes and
treatments of blood disorders. The mission of the Society is to further the understanding, diagnosis, treatment, and
prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems,
by promoting research, clinical care, education, training, and advocacy in hematology.